The role of molecular testing in digestive cancer treatment

Dr Estelle Cauchin
Nantes, France
Disclosure

Nothing to disclose
Personalized medicine

• There is no common definition of personalized medicine
Personalized medicine

• There is no common definition of personalized medicine

• According to the European Medicines Agency (EMA): "... give the right patient the right treatment, with each medication given the right dose, at the right time."

• In short, an ideal medicine because it is “tailor-made”. 
Personalized medicine

A multi-faceted approach to patient care
- In prevention (behavior, physical activity...)
- In detection of the disease at early stage
- To evaluate the risk of tumor (i.e., genetic predisposition)
- In accurate diagnosis
- In treatment
- In the management of treatment response and disease progression

*The age of personalized medicine, Personalized Medicine Coalition*
Personalized / Precision medicine

• Since 2012, opinion leaders started to abandon progressively « personalized medicine » in favor of « precision medicine »

• « Tailor-made » medicine was made possible by emerging technologies, in which genetics and genomics occupy a preponderant place

• A medicine which is adapted to individual patient, taking into account biomarkers and genetic characteristics.
Evolution of metastatic digestive cancer’s treatment


Best Supportive care
Chemotherapy by 5FU alone
Bi / Tri Chemotherapy
Targeted Therapy
Immunotherapy
Biomarkers
NGS
ctDNA

Precision medicine
Precision medicine: Key points

• **Why?** Prescription of certain precision medicine treatments is conditioned by the presence of specific molecular abnormalities in tumor cells

• **Goal?** Use of targeted therapies or immunotherapy can reduce the risk of disease progression

• **How?** Molecular testing to search for biomarkers

• **Which?** Biomarkers are biological markers which can influence therapeutic care
Tumor heterogeneity

Standard model for the evolution of cancer progression with massive tumor heterogeneity

Biomarkers

- Molecular abnormalities that may occur in the form of mutation or amplification.
- Molecular tests aim to detect possible biomarkers (molecular abnormalities) in a patient's tumor.
Targeted therapy

Blocking with targeted therapy

Messenger (growth factor)

Receptor

Transfer of information

Cancer Cell

Cell nucleus

Adapted from INCa France
Immunotherapy

PD-L1 protein

PD-1 receptor

Cancer cell

Inactive immune cell

Normal linkage of the defense system

Anti-PD-L1 treatment

Anti-PD-1 treatment

Cancer cell

Active immune cell

Normal linkage of the defense system

Adapted from INCa France
Main biomarkers in digestive tumors? Today and in future

• For colorectal cancer (RAS, BRAF, MSI...)
• For oesogastic cancer (HER2, ...)
• For cholangiocarcinoma (FGFR, IDH1/2, ...)
• For pancreatic cancer (BRCA 2/1, ...)
• For gastrointestinal stromal tumor (GIST) (KIT, PDGFRA, ...)
Great heterogeneity of colorectal cancer

- Consensuel Molecular Subtypes

<table>
<thead>
<tr>
<th>CMS1</th>
<th>CMS2</th>
<th>CMS3</th>
<th>CMS4</th>
</tr>
</thead>
<tbody>
<tr>
<td>MSI Immune</td>
<td>Canonical</td>
<td>Metabolic</td>
<td>Mesenchymal</td>
</tr>
<tr>
<td>14%</td>
<td>37%</td>
<td>13%</td>
<td>23%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>CMS1</th>
<th>CMS2</th>
<th>CMS3</th>
<th>CMS4</th>
</tr>
</thead>
<tbody>
<tr>
<td>MSI, CIMP high,</td>
<td>MS, CIMP high,</td>
<td>SCNA high</td>
<td>Mixed MSI status,</td>
<td>SCNA high</td>
</tr>
<tr>
<td>hypermutation</td>
<td>hypermutation,</td>
<td></td>
<td>SCNA low, CIMP low</td>
<td></td>
</tr>
<tr>
<td>BRAF mutations</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immune infiltration</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>and activation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WNT and MYC activation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>KRAS mutations</td>
<td></td>
<td></td>
<td></td>
<td>Stromal infiltration,</td>
</tr>
<tr>
<td>Metabolic deregulation</td>
<td></td>
<td></td>
<td></td>
<td>TGFβ activation,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>angiogenesis</td>
</tr>
</tbody>
</table>

Main biomarkers in metastatic colorectal cancer

• Newly diagnosed patients and those who have progressed after the treatment.

• Tumor testing for therapeutic purposes:
  – KRAS, NRAS, BRAF analysis
  – MMR proteins, MSI

• Can detect somatic (spontaneous) mutations to identify patients for targeted treatment.

• Requires biopsy tissue.
How are these analysis done?

- Prescription by clinician
- Transmission of material by the pathologist to the tumor genetics platform
- Return of results to clinician
- Analysis performed in 8-10 days

Adapted from Bruno Augusto Alves Martins et al. Front. Oncol., 27 November 2019
How are these analyzes done?

Development of molecular analyzes from blood, circulating tumor cells or circulating tumor DNA

Introducing next-generation sequencers (NGS) that allow multiple mutations to be analyzed in a single time on a sample

Adapted from Bruno Augusto Alves Martins et al. Front. Oncol., 27 November 2019
Main biomarkers in metastatic colorectal cancer (1)

RAS mutations (KRAS, NRAS)
- ≈ 50% of tumors
- Panitumumab or Cetuximab (anti-EGFR) are only allowed in patients with RAS wild type (non mutated) cancer
- Response rate: 30-40%
Main biomarkers in metastatic colorectal cancer (2)

**BRAF Mutations** *(V600E is the most frequent)*

- ≈ 10% of colorectal cancer
- Poor prognostic factor
- Resistance to anti-EGFR agents
- Intensified chemotherapy without anti-EGFR
- Combinations of anti-BRAF agents (oral) and anti-EGFR therapies after 1 or 2 prior treatment *(BEACON trial)*

Kopetz S et al. NEJM 2019; 381:1632-43
Main biomarkers in metastatic colorectal cancer (3)

**MicroSatellite Instability MSI**
- ≈ 5 to 15% of sporadic cancer
- Almost constant in Lynch syndrome
- Patient eligible to Immunotherapy trial?
Effectiveness of immunotherapy in MSI colorectal cancers

Fig. Overall survival of patients with metastatic colorectal cancer treated with pembrolizumab according to MSI status

Main biomarkers in metastatic colorectal cancer and therapeutic implication

Poor prognosis, limited treatment options:

- T cell transfer therapy
- Combination therapies targeting tumour microenvironment

Main biomarkers:
- MSI-H POLE
- RAS WT
- RAS mut
- BRAF V600E
- CMS4

Biomarker interactions:
- ~5% Immune checkpoint inhibition
- ~2% RET/ALK/NTRK/ROS1 fusions
- ~2% Tyrosine kinase inhibitors
- 2–5% Dual HER2 inhibition
- ~10% ERBB2 amp
- >25% BRAF inhibition/anti-EGFR antibodies/irinotecan (or MEK inhibition)

Treatment options:
- Tyrosine kinase inhibitors
- Dual HER2 inhibition
- BRAF V600E

Adapted from Sveen A et al. Nat Rev 2020: 17; 11-32
Main biomarkers in colorectal cancer
The oncogenetic approach

• If personal or family history of cancer:
  – Analysis of expression of MMR proteins
  – and/or MSI analysis

• Germline testing (digestive panel) using blood or saliva

• Can detect inherited mutations

• These inherited mutations can be transmitted to progeny (hereditary transmission)

• Can be used for testing the relatives and guide the genetic counselling in the family
The oncogenetic approach
The genetic counselling

What is my risk of cancer if Lynch syndrome (germline mutation)?
The oncogenetic approach
The genetic counselling

Predictive genetic testing in order to adapt surveillance & prevention for each relative
Keys messages

• Only few targeted oncology drugs available in gastrointestinal cancer compared to other tumors
• Better clinical, histological, and molecular characterization of digestive cancers necessary
• Most established biomarkers have a low prevalence (HER2)
• Immunotherapy and MSI colorectal cancer
• Genetic counselling if MSI tumors
• Expected progress in the future thanks to next-generation sequencers (NGS) approach with new potential targets
• ctDNA analysis to anticipate disease progression
Thank you for your attention